Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 3/20 | 0.34 |
| ▸ | OXTR | P30559 | 2/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.33 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 3/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.32 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | ACLY | P53396 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2451254 | 0.90 | GRM5 (0.35) | PIK3CAOXTRGRM5KCNH2STIM1 | |
| SCHEMBL2448152 | 0.88 | PIK3CA (0.35) | PIK3CAOXTRAVPR1AGRM5STIM1 | |
| SCHEMBL2452981 | 0.85 | OXTR (0.46) | OXTRAVPR1A | |
| SCHEMBL1074623 | 0.84 | PIK3CA (0.41) | PIK3CAKCNH2GRM1 | |
| SCHEMBL1074256 | 0.82 | GRM1 (0.43) | KCNH2PDE4BGRM1 | |
| SCHEMBL2452818 | 0.81 | PIK3CA (0.41) | PIK3CAMTORGLAPIK3CD | |
| SCHEMBL1074563 | 0.79 | NOTUM (0.37) | GLA | |
| SCHEMBL1074021 | 0.78 | PTGS1 (0.35) | PIK3CAOXTRAVPR1AGRM5STIM1 | |
| SCHEMBL2451262 | 0.78 | PIK3CA (0.35) | PIK3CAOXTRAVPR1AGRM5STIM1 | |
| SCHEMBL2451452 | 0.77 | OXTR (0.44) | OXTRAVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110311649-A1 | NOVEL IMIDAZOLE DERIVATIVES | SYNGENTA CROP PROTECTION, INC. (US) | 2011-12-22 | — | — | US | disclosed |
| EP-2201001-B1 | NOVEL IMIDAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2011-09-14 | — | — | EP | disclosed |
| EP-2201001-A1 | NOVEL IMIDAZOLE DERIVATIVES | Syngenta Participations AG (CH) | 2010-06-30 | — | — | EP | disclosed |
| WO-2009053101-A1 | NOVEL IMIDAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2009-04-30 | — | — | WO | disclosed |
| EP-2053046-A1 | Novel imidazole derivatives | Syngeta Participations AG (CH) | 2009-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110311649-A1 | NOVEL IMIDAZOLE DERIVATIVES | CBR3, C3AR1, C1R | PIK3CA 2874/4885OXTR 1079/4885P2RX7 365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.